# Viracta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viracta-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.viracta.com
- Total disclosed funding: $118M
- Latest round: Series E (Nov 25, 2020)
- Investors on record: 11

## About

Based in California, US, and founded in 2007, Viracta Therapeutics, Inc., formerly known as HemaQuest Pharmaceuticals, Inc. is a precision oncology company that focuses on virus-related diseases. Ivor Royston, M.D., is the current President and Chief Executive Officer of the company. In 2020, Sunesis Pharmaceuticals, Inc. merged with the company, and in February 2021, Viracta Therapeutics raised USD 65 million in PIPE funding led by new investor BVF Partners, with participation from other new investors. 

The company offers a combination approach to treat a range of viral-associated cancers and other serious diseases. Viracta’s proprietary investigational drug called nanatinostat in combination with the antiviral agent valganciclovir is a novel therapeutic approach to targeting EBV+ lymphoma. The company is also looking at using its inducible synthetic lethality technique in other EBV-related diseases, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

Following the merger with Sunesis Pharmaceuticals, the company intends to continue advancing and expanding Viracta's clinical-stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma.

## Funding rounds

- Series E, Nov 25, 2020, $40M — Latterell Venture Partners, aMoon, LifeSci Partners, Taiwania Capital
- Series D, Oct 28, 2019, $17M — Taiwania Capital
- Series B, Apr 4, 2017, $18M — Forward Ventures, Latterell Venture Partners, Wicklow Capital, NantKwest, Inc.
- Series B, Mar 12, 2012, $6.5M — Forward Ventures, Latterell Venture Partners, Aberdare Ventures, Lilly Ventures, De Novo Ventures
- Series B, Jul 28, 2010, $4M — Latterell Venture Partners
- Series B, Apr 19, 2010, $6M — Forward Ventures, Aberdare Ventures, Lilly Ventures, De Novo Ventures
- Series B, Jan 29, 2010, $6M — Lilly Ventures, De Novo Ventures, Forward Venture Capital
- Series A, Nov 1, 2007, $20M — Forward Ventures, Lilly Ventures, De Novo Ventures

## Investors

- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series B
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A, Series B
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series A, Series B
- Forward Venture Capital (https://capitalatlas.ai/funds/forward-venture-capital) — Series B
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series B
- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series B, Series E
- Wicklow Capital — Series B
- NantKwest, Inc. — Series B
- Taiwania Capital (https://capitalatlas.ai/funds/taiwania-capital) — Series D, Series E
- aMoon (https://capitalatlas.ai/funds/amoon) — Series E
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series E